For: | Jamall IS, Yusuf S, Azhar M, Jamall S. Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3? World J Gastroenterol 2008; 14(43): 6627-6631 [PMID: 19034963 DOI: 10.3748/wjg.14.6627] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v14/i43/6627.htm |
Number | Citing Articles |
1 |
Nicola Schiano Moriello, Biagio Pinchera, Ivan Gentile. Personalized care approaches to hepatitis C therapy: recent advances and future directions. Expert Review of Anti-infective Therapy 2024; 22(4): 139 doi: 10.1080/14787210.2024.2328336
|
2 |
Hanadi Qashqari, Amany Al-Mars, Adeel Chaudhary, Adel Abuzenadah, Ghazi Damanhouri, Mohammed Alqahtani, Maged Mahmoud, Maysaa El Sayed Zaki, Kaneez Fatima, Ishtiaq Qadri. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance. Infection, Genetics and Evolution 2013; 19: 113 doi: 10.1016/j.meegid.2013.06.025
|
3 |
|
4 |
Masoud Keikha, Majid Eslami, Bahman Yousefi, Mohammad Ali-Hassanzadeh, Ali Kamali, Masoud Yousefi, Mohsen Karbalaei. HCV genotypes and their determinative role in hepatitis C treatment. VirusDisease 2020; 31(3): 235 doi: 10.1007/s13337-020-00592-0
|
5 |
Molecular study of HCV detection, genotypes and their routes of transmission in North West Frontier Province, Pakistan. Asian Pacific Journal of Tropical Biomedicine 2012; 2(7): 532 doi: 10.1016/S2221-1691(12)60091-4
|
6 |
W.M.S. Degrave, L. Mendonça-Lima. Current Developments in Biotechnology and Bioengineering. 2017; : 51 doi: 10.1016/B978-0-444-63660-7.00003-6
|
7 |
Jing-Hong Hu, Ming-Ling Chang, Tung-Jung Huang, Chau-Ting Yeh, Wen-Nan Chiu, Ming-Shih Chiang, Mei-Yen Chen. Comparison of Compliance and Efficacy of Pegylated Interferon α-2a and α-2b in Adults with Chronic Hepatitis C. Journal of Interferon & Cytokine Research 2019; 39(4): 205 doi: 10.1089/jir.2018.0028
|
8 |
Yan Guan, Huiyong Sun, Youyong Li, Peichen Pan, Dan Li, Tingjun Hou. The competitive binding between inhibitors and substrates of HCV NS3/4A protease: A general mechanism of drug resistance. Antiviral Research 2014; 103: 60 doi: 10.1016/j.antiviral.2014.01.010
|
9 |
Bernhard Kutscher. Ullmann's Encyclopedia of Industrial Chemistry. 2021; : 1 doi: 10.1002/14356007.w23_w07
|
10 |
Mortada El-Shabrawi, Mona Isa. Commentary on: The optimal Dose of Ribavirin for Chronic Hepatitis C: From Literature Evidence to Clinical Practice. Hepatitis Monthly 2013; 13(2) doi: 10.5812/hepatmon.7867
|